Press Release: Assembly Bio : Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
- Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 -
Read full article »
Assembly Bio is a California-based biopharmaceutical company that researches and develops microbiome therapeutics for the treatment of hepatitis B and infectious diseases.
Read more